Log on / register
Feedback | Support | My details
Open AccessResearch article

Is expanding Medicare coverage cost-effective?

Peter Franks1* email, Peter Muennig2* email and Marthe Gold3 email

Center for Health Services Research in Primary Care, Department of Family & Community Medicine, University of California, Davis, Sacramento, CA, USA

Department of Health Policy and Management, Mailman School of Public Health, Columbia University, New York, NY, USA

City University of New York Medical School, New York, NY, USA

author email corresponding author email* Contributed equally

BMC Health Services Research 2005, 5:23doi:10.1186/1472-6963-5-23

Published: 14 March 2005

Abstract

Background

Proposals to expand Medicare coverage tend to be expensive, but the value of services purchased is not known. This study evaluates the efficiency of the average private supplemental insurance plan for Medicare recipients.

Methods

Data from the National Health Interview Survey, the National Death Index, and the Medical Expenditure Panel Survey were analyzed to estimate the costs, changes in life expectancy, and health-related quality of life gains associated with providing private supplemental insurance coverage for Medicare beneficiaries. Model inputs included socio-demographic, health, and health behavior characteristics.

Parameter estimates from regression models were used to predict quality-adjusted life years (QALYs) and costs associated with private supplemental insurance relative to Medicare only. Markov decision analysis modeling was then employed to calculate incremental cost-effectiveness ratios.

Results

Medicare supplemental insurance is associated with increased health care utilization, but the additional costs associated with this utilization are offset by gains in quality-adjusted life expectancy. The incremental cost-effectiveness of private supplemental insurance is approximately $24,000 per QALY gained relative to Medicare alone.

Conclusion

Supplemental insurance for Medicare beneficiaries is a good value, with an incremental cost-effectiveness ratio comparable to medical interventions commonly deemed worthwhile.


© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.